Y06137
Y06137 is a potent and selective BET inhibitor for treatment of castration-resistant prostate cancer (CRPC) . Y06137 binds to the BRD4 (1) bromodomain with a Kd of 81 nM[1].
Product Specifications
CAS Number
2226534-49-0
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Y06137.html
Purity
99.90
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
CC1=NOC(C1=C2)=CC=C2C3=NC(C=C4)=C(N3CC5CCCCC5)C=C4N6CCOC[C@@H]6C
Molecular Formula
C27H32N4O2
Molecular Weight
444.57
References & Citations
[1]Zhang M, et al. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC) . J Med Chem. 2018 Apr 12;61 (7) :3037-3058.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2200-100 1x 100 µL
Cytokeratin 7 (Glandular and Transitional Epithelial Marker) (KRT7/2200), 0.2mg/mL
Sign In for Pricing
View Details 
KN221382 1 Kit
Nicotinic Acetylcholine Receptor alpha 7 (CHRNA7) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 
TRC-B423265-500MG 500 mg
Bis(1,5-cyclooctadiene)diiridium(I) Dichloride
Sign In for Pricing
View Details